IP Library Granted Patent US 8,034,775
Granted Patent B2
US 8,034,775 · App. 11/929,822 · Granted Oct 11, 2011

Kallikrein-inhibitor therapies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,034,775
App. No.
11/929,822
Granted
Oct 11, 2011
Kind
B2
Abstract

Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient.

Claims (15)

1. A method for reducing blood loss in a patient, the method comprising administering to the patient a composition comprising an effective amount of a kallikrein inhibitor, wherein the inhibitor comprises a polypeptide that comprises the amino acid sequence of SEQ ID NO:57.

2. The method of claim 1 , wherein the blood loss is perioperative blood loss due to a surgical procedure performed on the patient.

3. The method of claim 2 , wherein the surgical procedure is a cardiothoracic surgery.

4. The method of claim 3 , wherein the cardiothoracic surgery is cardiopulmonary bypass or coronary artery bypass grafting.

5. The method of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2.

6. The method of claim 1 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO:57.

7. The method of claim 1 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO:2.

8. The method of claim 3 , wherein the cardiothoracic surgery is pediatric cardiothoracic surgery.

9. The method of claim 2 , wherein the surgical procedure is hip replacement surgery.

10. The method of claim 2 , wherein the surgical procedure is lung transplantation.

11. The method of claim 2 , wherein the surgical procedure is an orthopic liver transplant.

12. The method of claim 2 , wherein the surgical procedure is a procedure utilizing extracorporeal circulation.

13. The method of claim 2 , wherein the polypeptide is administered prior to the surgical procedure.

14. The method of claim 2 , wherein the polypeptide is administered during the surgical procedure.

15. The method of claim 2 , wherein the polypeptide is administered after the surgical procedure.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2021
From: DYAX CORP.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 056268/0983 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2008
From: LADNER, ROBERT C.; LEY, ARTHUR C.; HIRANI, SHIRISH; WILLIAMS, ANTHONY
To: DYAX CORP.
Reel/Frame 020688/0862 →